date_text,stage,ticker,price,end_date,drug
,Phase 2,TCON,2.90,02/10/2018,DE-122 and Lucentis - AVANTE
,PDUFA,AMAG,12.95,02/14/2018,Makena - auto injector
,PDUFA,ATRS,2.06,02/14/2018,Makena - auto injector
"February 14-17, 2018;",Phase 2,CELG,92.51,02/14/2018,OTEZLA
Adcom 2/14/18; PDUFA 4/6/18;,PDUFA,PCRX,37.40,02/14/2018,EXPAREL
"February 15-17, 2018;",Phase 2,KURA,19.00,02/15/2018,Tipifarnib
,PDUFA,APRI,2.31,02/17/2018,Vitaros
,Phase 2,IMNP,0.53,02/17/2018,Bertilimumab
,PDUFA,KMPH,5.75,02/23/2018,KP201/APAP
February 2018;,Phase 3,AIMT,38.68,02/28/2018,AR101 PALISADE
February 2018;,Phase 1/2,AST,1.95,02/28/2018,AST-OPC1 SCiSTAR
Early 2018;,Phase 3,CRMD,0.44,02/28/2018,Neutrolin - LOCK-IT 100
,Phase 2,HTBX,2.61,02/28/2018,HS-110 and nivolumab (Opdivo)
February 2018;,Phase 2,KDMN,4.79,02/28/2018,KD025
Early 2018;,Phase 2,MRNS,6.01,02/28/2018,Ganaxolone
Feb 2018;,Phase 1/2,NVAX,1.98,02/28/2018,NanoFlu vaccine
Early 2018;,Phase 1/2,RXII,3.12,02/28/2018,RXI-109-1501
,PDUFA,SRNE,6.80,02/28/2018,ZTlido (lidocaine patch 1.8%)
February 2018;,Phase 1,SRRA,2.74,02/28/2018,SRA737
,PDUFA priority review,VRTX,152.96,02/28/2018,Tezacaftor (VX-661) / ivacaftor
"February 26-March 1, 2018;",Phase 1/2,IONS,46.75,03/01/2018,IONIS-HTT Rx
,PDUFA,OTIC,5.30,03/02/2018,OTIPRIO
,PDUFA,BMY,62.70,03/05/2018,Opdivo -  4 week applications
,PDUFA,PFE,34.16,03/08/2018,Xeljanz
,Phase 3,REGN,336.38,03/10/2018,Praluent (alirocumab) ODYSSEY OUTCOMES
"March 11-14, 2018;",Phase 1,SYBX,9.54,03/11/2018,SYNB1020
,Phase 2,SLS,5.26,03/19/2018,Galinpepimut-S
"March 24-27, 2018;",Phase 1b,IMGN,8.91,03/24/2018,Mirvetuximab soravtansine - FORWARD II
,PDUFA,AMGN,173.46,03/29/2018,BLINCYTO
March 2018;,Phase 2b,ABIO,1.60,03/31/2018,Gencaro - GENETIC-AF trial
1Q 2018;,Phase 3,ACOR,24.05,03/31/2018,Tozadenant
1Q 2018;,Phase 1/2,ALT,1.56,03/31/2018,NasoVAX
1Q 2018;,Phase 2a,ANAB,104.33,03/31/2018,ANB020
1Q 2018;,Phase 3,ANTH,1.56,03/31/2018,Sollpura - RESULT
Early 2018;,Phase 3,ARMO,38.30,03/31/2018,AM0010 (PEG-IL-10)
1Q or 2Q 2018;,Phase 2,ARNA,39.71,03/31/2018,APD371
1Q 2018;,Phase 2,ARNA,39.71,03/31/2018,Etrasimod
1Q 2018;,Phase 3,BHVN,29.71,03/31/2018,Rimegepant
Early 2018;,Phase 2,BPTH,1.85,03/31/2018,Prexigebersen
1Q 2018;,Phase 2,CDTX,6.40,03/31/2018,Rezafungin (CD101) IV - STRIVE
1Q 2018;,Phase 3,CLSD,5.77,03/31/2018,Suprachoroidal CLS-TA - PEACHTREE
1Q 2018;,Phase 2,CORT,14.59,03/31/2018,CORT125134
1Q 2018;,Phase 2,CYTK,8.55,03/31/2018,CK-2127107
1Q 2018;,Phase 3,DERM,26.79,03/31/2018,Olumacostat glasaretil (DRM01)
1Q 2018 - likely February;,Phase 3,EARS,0.27,03/31/2018,Keyzilen (AM-101) - TACTT3
1Q 2018;,Phase 3,EDGE,13.28,03/31/2018,EG-1962
1Q 2018;,Phase 2,ESPR,69.46,03/31/2018,Bempedoic Acid - 1002-039
"March, May and September 2018;",Phase 3,ESPR,69.46,03/31/2018,"Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048"
1Q 2018;,Phase 2,FLKS,4.17,03/31/2018,FLX-787 (Aust)
1Q 2018;,Phase 2,GERN,2.25,03/31/2018,Imetelstat - IMbarkStudy
1Q 2018;,Phase 3,GILD,79.32,03/31/2018,Bictegravir/F/TAF
1Q 2018;,Phase 3,GILD,79.32,03/31/2018,GS-5745
1Q 2018;,Phase 2,GILD,79.32,03/31/2018,GS-9674
1Q 2018;,Phase 2,GILD,79.32,03/31/2018,Entospletinib
1Q 2018;,Phase 2,GLMD,9.70,03/31/2018,Aramchol - ARRIVE
1Q 2018;,Phase 2,GTHX,19.38,03/31/2018,Trilaciclib
1Q 2018;,Phase 3,GWPH,126.06,03/31/2018,Epidiolex
1Q 2018;,Phase 2,GWPH,126.06,03/31/2018,GWP42006 (CBDV)
1Q 2018;,Phase 3,IMGN,8.91,03/31/2018,Mirvetuximab soravtansine - FORWARD I
1Q 2018;,Phase 2,IMRN,7.54,03/31/2018,IMM-124E
Early 2018;,Phase 1,MBIO,10.14,03/31/2018,MB-102
Early 2018;,Phase 1,MBIO,10.14,03/31/2018,MB-101
1Q 2018;,Phase 1,MBVX,0.90,03/31/2018,MVT-1075
1Q 2018;,Phase 1/2,MBVX,0.90,03/31/2018,MVT-5873
Early 2018;,Phase 1b,MCRB,8.45,03/31/2018,SER-262
1Q 2018;,Phase 2b,MESO,5.09,03/31/2018,MPC-150-IM - Class IV
1Q 2018;,Phase 3,MESO,5.09,03/31/2018,MSC-100-IV
1Q 2018 - see note below;,Phase 2,MRTX,27.10,03/31/2018,Mocetinostat and durvalumab
1Q 2018;,Phase 2,MYOK,47.50,03/31/2018,MYK-461 - PIONEER-HCM
1Q 2018;,Phase 3,NBIX,79.28,03/31/2018,Elagolix
1Q 2018;,Phase 3,NVO,50.07,03/31/2018,Semaglutide - oral - PIONEER
1Q 2018;,Phase 2,OBSV,12.19,03/31/2018,OBE001 - IMPLANT2
1Q 2018;,Phase 2,PLX,0.63,03/31/2018,OPRX-106
Early 2018;,Phase 2b,PTGX,17.58,03/31/2018,PTG-100
1Q 2018;,Phase 1,PTI,2.74,03/31/2018,PTI-428 + Kalydeco
1Q 2018;,Phase 2,RETA,26.22,03/31/2018,Bardoxolone methyl - LARIAT
1Q 2018;,Phase 2,RETA,26.22,03/31/2018,Omaveloxolone - MOTOR
1Q 2018;,Phase 1/2,RGLS,1.11,03/31/2018,RG-012
1Q 2018;,Phase 2b,SLS,5.26,03/31/2018,NeuVax in combination with Herceptin
Late-1Q 2018;,Phase 2,SPHS,2.05,03/31/2018,Topsalysin (PRX302)
1Q 2018;,Phase 3,TTPH,5.15,03/31/2018,Eravacycline (TP-434) - IGNITE3
1Q 2018;,Phase 3,VBLT,6.45,03/31/2018,VB-111
1Q 2018;,Phase 2,VNDA,15.63,03/31/2018,HETLIOZ (tasimelteon)
1Q 2018;,Phase 2,VRTX,152.96,03/31/2018,VX-150
Early 2018;,Phase 1/2,VTVT,6.49,03/31/2018,TTP399
Early 2018;,Phase 3,VTVT,6.49,03/31/2018,Azeliragon - STEADFAST
1Q 2018;,Phase 1b,VYGR,18.18,03/31/2018,VY-AADC01
,PDUFA priority review,MRK,54.87,04/03/2018,Keytruda
,PDUFA,THERF,5.55,04/03/2018,Ibalizumab
,PDUFA priority review,CLVS,50.92,04/06/2018,Rucaparib ARIEL3
"April 7-10, 2018;",Phase 3,NVS,83.25,04/09/2018,AIN457 (Cosentyx)
EASL 2018.;,Phase 2,EIGR,8.15,04/11/2018,Pegylated Interferon Lambda (LIMT HDV)
,PDUFA priority review,LLY,76.23,04/12/2018,Abemaciclib - MONARCH 3
1H April 2018;,Phase 2,SELB,8.49,04/13/2018,SEL-212
,PDUFA priority review,BMY,62.70,04/16/2018,CM-214 – Opdivo + Yervoy
,PDUFA priority review,RARE,44.47,04/17/2018,KRN23 Burosumab
,PDUFA,RIGL,3.79,04/17/2018,Fostamatinib
,Phase 2,MNOV,9.45,04/27/2018,MN-166
,PDUFA priority review,NBIX,79.28,04/27/2018,Elagolix
,PDUFA,SCMP,18.00,04/28/2018,Lubiprostone
Fall 2018;,Phase 3,ALKS,53.89,04/30/2018,ALKS 3831 - ENLIGHTEN-2
,PDUFA,AMGN,173.46,04/30/2018,KYPROLIS (ENDEAVOR)
"ARVO Conference - Apr 29 - May 03, 2018;",Phase 1/2,BTX,2.58,04/30/2018,OpRegen
April 2018;,Phase 2b,KPTI,13.06,04/30/2018,Selinexor - STORM
Spring 2018;,Phase 3,NBRV,5.37,04/30/2018,Lefamulin - LEAP 2
,PDUFA priority review,NVS,83.25,04/30/2018,Kymriah (CTL019 )- JULIET
,PDUFA priority review,PGNX,5.42,04/30/2018,Azedra
,PDUFA priority review,SGEN,50.14,05/01/2018,ADCETRIS  in combination with chemotherapy ECHELON-1
,PDUFA,PTLA,44.41,05/04/2018,Andexanet alfa
,PDUFA,LPCN,1.23,05/08/2018,LPCN 1021
,PDUFA,VRX,17.79,05/13/2018,Plenvu (NER1006)
Estimate mid-2Q 2018;,PDUFA priority review,AZN,33.61,05/15/2018,Tagrisso - FLAURA
,PDUFA,AMGN,173.46,05/17/2018,Erenumab
,PDUFA,NVS,83.25,05/17/2018,Erenumab
,PDUFA priority review,DOVA,30.58,05/21/2018,Avatrombopag
,PDUFA priority review,JNJ,129.53,05/21/2018,DARZALEX (Daratumumab) - ALCYONE
,PDUFA priority review,BMRN,80.33,05/25/2018,Pegvaliase
,PDUFA,REPH,7.84,05/26/2018,Intravenous (IV) meloxicam
,PDUFA,AMGN,173.46,05/28/2018,Prolia (denosumab)
,PDUFA,TXMD,5.41,05/29/2018,Yuvvexy - TX-004HR
May 2018;,Phase 3,ESPR,69.46,05/31/2018,Bempedoic acid (ETC-1002-040) - Clear Harmony
,PDUFA,KTOV,2.38,05/31/2018,KIT-302
Estimate mid-2Q 2018;,PDUFA priority review,NVS,83.25,05/31/2018,Tafinlar (dabrafenib) and Mekinist (trametinib)
ASCO 2018;,Phase 2,IDRA,1.92,06/01/2018,IMO-2125 + ipilimumab - ILLUMINATE 204
,PDUFA,VRX,17.79,06/18/2018,IDP-118
,PDUFA,SCPH,12.00,06/23/2018,Furoscix
,PDUFA priority review,AKAO,10.54,06/25/2018,Plazomicin
,PDUFA priority review,GWPH,126.06,06/27/2018,Epidiolex
2Q 2018;,Phase 2,ABBV,111.30,06/30/2018,Rova-T (TRINITY)
1H 2018;,Phase 2,ACRS,19.01,06/30/2018,ATI-50002 - PK/safety
1H 2018;,Phase 2,ACRS,19.01,06/30/2018,ATI-50002 - open label
2Q 2018;,Phase 3,ADMS,33.87,06/30/2018,GOCOVRI (amantadine)
1H 2018;,Phase 3,AGN,162.77,06/30/2018,UBROGEPANT - ACHIEVE II (UBR-MD-02)
1H 2018;,Phase 3,AGN,162.77,06/30/2018,Cariprazine
1H 2018;,Phase 2b,AGN,162.77,06/30/2018,ATOGEPANT
1H 2018;,PDUFA,AGN,162.77,06/30/2018,ESMYA  (ulipristal acetate)
1H 2018;,Phase 2a,ALRN,7.88,06/30/2018,ALRN-6924
2Q 2018;,Phase 2a,ANAB,104.33,06/30/2018,ANB020
1H 2018;,Phase 3,ANIK,57.59,06/30/2018,Cingal
1H 2018;,Phase 3,APLS,14.01,06/30/2018,APL-2 IV - FILLY
1H 2018;,Phase 3,ARGS,1.58,06/30/2018,rocapuldencel-T (AGS-003) ADAPT Trial
1H 2018;,Phase 1,ARGS,1.58,06/30/2018,AGS-004 and vorinostat
,PDUFA,ARRY,17.03,06/30/2018,Binimetinib - COLUMBUS
1H 2018;,Phase 2,ASNS,12.02,06/30/2018,ASN100
2Q 2018;,Phase 3,AVEO,3.05,06/30/2018,TIVO-3 - tivozanib
2Q 2018;,Phase 2,AVIR,0.76,06/30/2018,BTA074 5% topical gel
1H 2018;,Phase 3,AXSM,2.50,06/30/2018,AXS-05 STRIDE-1
1H 2018;,Phase 3,AZN,33.61,06/30/2018,Selumetinib - ASTRA
1H 2018;,Phase 3,AZN,33.61,06/30/2018,Lynparza
1H 2018;,Phase 3,AZN,33.61,06/30/2018,Durvalumab +/- tremelimumab (MYSTIC)
1H 2018;,Phase 3,AZN,33.61,06/30/2018,Durvalumab +/- tremelimumab (KESTREL)
1H 2018;,Phase 3,AZN,33.61,06/30/2018,Durvalumab +/- tremelimumab (EAGLE)
1H 2018;,Phase 3,AZN,33.61,06/30/2018,Durvalumab +/- tremelimumab (ARCTIC)
1H 2018;,Phase 3,BMY,62.70,06/30/2018,CM-511 – Opdivo + Yervoy
1H 2018;,Phase 3,BMY,62.70,06/30/2018,CM-331– Opdivo
1H 2018;,Phase 3,BMY,62.70,06/30/2018,CM-227 – Opdivo + Yervoy
1H 2018;,Phase 2,BMY,62.70,06/30/2018,CM-548 - Opdivo+SOC
2Q 2018;,Phase 1/2,BOLD,31.33,06/30/2018,AT342 - VALENS
1H 2018;,Phase 2,CBIO,32.15,06/30/2018,Marzeptacog alfa
1H 2018;,Phase 3,CELG,92.51,06/30/2018,REVLIMID - AUGMENT NHL-007
1H 2018;,Phase 1/2,CKPT,4.42,06/30/2018,CK-101
2Q 2018;,Phase 2b,CLDX,2.38,06/30/2018,Glembatumumab vedotin
2Q 2018;,Phase 2,CLSD,5.77,06/30/2018,Suprachoroidal CLS-TA - TYBEE
2Q 2018;,Phase 1/2,CLSD,5.77,06/30/2018,Suprachoroidal CLS-TA - HULK
1H 2018;,Phase 2b,CNAT,5.06,06/30/2018,Emricasan
1H 2018;,Phase 1,CORI,12.18,06/30/2018,Corplex Donepezil
1H 2018;,Phase 3,CPRX,3.28,06/30/2018,Firdapse
1H 2018;,Phase 3,CTIC,3.21,06/30/2018,PIXUVRI - PIX306 Trial
1H 2018;,Phase 2b,DBVT,21.25,06/30/2018,Viaskin Milk
,PDUFA,DERM,26.79,06/30/2018,Glycopyrronium tosylate (DRM04)
1H 2018;,Phase 1,DNLI,21.49,06/30/2018,DNL201
1H 2018;,Phase 3,EXEL,28.21,06/30/2018,IMblaze370 - cobimetinib and atezolizumab
2Q 2018;,Phase 3,EYEG,0.67,06/30/2018,EGP-437
1H 2018;,Phase 2,FBIO,3.63,06/30/2018,CEVA101
1H 2018;,Phase 2,FBIO,3.63,06/30/2018,Pepvax vaccine
2Q 2018;,Phase 3,FBIO,3.63,06/30/2018,IV Tramadol
2Q 2018;,Phase 2b,GEMP,6.38,06/30/2018,Gemcabene - INDIGO-1
2Q 2018;,Phase 2,GILD,79.32,06/30/2018,Selonsertib (GS-4997)
2Q 2018;,Phase 2,GILD,79.32,06/30/2018,GS-9674
2Q 2018;,Phase 2b,GLMD,9.70,06/30/2018,Aramchol - ARREST
1H 2018;,Phase 2,GLPG,108.83,06/30/2018,GLPG2737 - PELICAN
2Q 2018;,Phase 2,GLPG,108.83,06/30/2018,Filgotinib - TORTUGA
2Q 2018;,Phase 2,GLPG,108.83,06/30/2018,Filgotinib - EQUATOR
2Q 2018;,Phase 1b,GTHX,19.38,06/30/2018,G1T38 plus Faslodex
1H 2018;,Phase 3,HRTX,20.50,06/30/2018,HTX-011
2Q 2018;,Phase 2,IDRA,1.92,06/30/2018,IMO-8400
1H 2018;,Phase 1,IMMP,1.74,06/30/2018,Eftilagimod alpha and Keytruda
1H 2018;,Phase 3,INCY,84.50,06/30/2018,Epacadostat with Keytruda - ECHO-301
1H 2018;,Phase 3,INCY,84.50,06/30/2018,Ruxolitinib - REACH 1
2Q 2018;,Phase 1,INFI,1.97,06/30/2018,IPI-549 + Nivolumab
1H 2018;,Phase 1/2,JNCE,23.77,06/30/2018,JTX-2011
2018;,Phase 3,JNJ,129.53,06/30/2018,Esketamine
2Q 2018;,Phase 3,KMPH,5.75,06/30/2018,KP415
1H 2018;,Phase 2,KURA,19.00,06/30/2018,Tipifarnib
1H 2018;,Phase 2,MACK,10.00,06/30/2018,MM-141 - CARRIE
1H 2018;,Phase 3,MDWD,4.20,06/30/2018,NexoBrid
2Q 2018;,Phase 1,MEIP,2.14,06/30/2018,ME-401
2Q 2018;,Phase 1,MEIP,2.14,06/30/2018,ME-344
2Q 2018;,Phase 2,MEIP,2.14,06/30/2018,Pracinostat in combination with Vidaza
1H 2018;,Phase 2,MGNX,22.66,06/30/2018,Margetuximab in combination with pembrolizumab
2Q 2018;,Phase 2,MNLO,35.65,06/30/2018,Serlopitant
"1H 2018 (est, only);",Phase 3,MRK,54.87,06/30/2018,(MK-3475-189/KEYNOTE-189)
2Q 2018;,Phase 2,MTNB,0.89,06/30/2018,MAT2501
1H 2018;,Phase 2a,NBIX,79.28,06/30/2018,NBI-74788
1H 2018;,Phase 2,NLNK,6.81,06/30/2018,Indoximod + gemcitabine and nab-paclitaxel
1H 2018;,Phase 2,NVS,83.25,06/30/2018,LJN452
2Q 2018;,Phase 3,NVS,83.25,06/30/2018,LEE011: MONALEESA-3
1H 2018;,Phase 3,PBYI,60.85,06/30/2018,Neratinib
1H 2018;,Phase 3,PFNX,3.11,06/30/2018,PF708 and Forteo
2Q 2018;,Phase 2b,PRTA,28.19,06/30/2018,NEOD001 PRONTO
2Q 2018;,Phase 2,PSTI,1.33,06/30/2018,PLX-PAD (stem cells)
2Q 2018;,Phase 2a,RNN,1.90,06/30/2018,Supinoxin
1H 2018;,Phase 1b,RXDX,26.95,06/30/2018,RXDX-105
1Q/2Q 2018;,Phase 2,RXII,3.12,06/30/2018,Samcyprone - RXI-SCP-1502
1H 2018;,Phase 2,RYTM,25.76,06/30/2018,Setmelanotide
2Q 2018;,Phase 3,SBBP,6.60,06/30/2018,COR-003 (levoketoconazole) - SONICS
1H 2018;,Phase 1/2,SGMO,19.60,06/30/2018,SB-525 cDNA gene therapy
1H 2018;,Phase 1/2,SGMO,19.60,06/30/2018,SB-318
1H 2018;,Phase 1/2,SGMO,19.60,06/30/2018,SB-913 - CHAMPIONS
1H 2018;,Phase 1/2,SNDX,8.98,06/30/2018,Entinostat plus Keytruda - ENCORE 601
1H 2018;,Phase 3,SNDX,8.98,06/30/2018,E2112
1H 2018;,Phase 1b,SPRO,11.88,06/30/2018,SPR741
1H 2018;,Phase 2,SVRA,11.70,06/30/2018,Aironite - INDIE
1H 2018;,Phase 2a,TBPH,27.95,06/30/2018,TD-9855
1H 2018;,Phase 1/2,TCON,2.90,06/30/2018,TRC253
1H 2018;,Phase 2,TCON,2.90,06/30/2018,TRC105 and Inlyta
2Q 2018;,Phase 3,TGTX,11.75,06/30/2018,TG-1101 and TGR-1202 - UNITY-CLL study
1H 2018;,Phase 2/3,TOCA,11.37,06/30/2018,Toca 511 & Toca FC
1H 2018;,Phase 2,TPIV,3.49,06/30/2018,TPIV200
1H 2018;,Phase 1/2,TSRO,58.89,06/30/2018,Niraparib and Keytruda (TOPACIO)
1H 2018;,Phase 1/2,TTNP,1.20,06/30/2018,Ropinirole implant
2Q 2018;,Phase 2,VICL,1.45,06/30/2018,VCL-HB01 HSV-2 Therapeutic Vaccine
1H 2018;,Phase 2,VKTX,6.35,06/30/2018,VK2809
1H 2018;,Phase 2a,VRNA,11.85,06/30/2018,RPL554
1H 2018;,Phase 2,VRTX,152.96,06/30/2018,VX-445 in combination with tezacaftor and ivacaftor
1H 2018;,Phase 2,XLRN,39.23,06/30/2018,ACE-083
2Q 2018;,Phase 3,ZEAL,15.28,06/30/2018,Dasiglucagon
2Q 2018;,Phase 3,ZGNX,37.75,06/30/2018,ZX008 - Study 1504
,PDUFA priority review,IONS,46.75,07/06/2018,Inotersen (IONIS-TTRRx)
,PDUFA,DRRX,1.09,07/28/2018,RBP-7000
,PDUFA,INSY,7.65,07/28/2018,Buprenorphine
Mid-2018;,Phase 3,ALNY,115.92,07/31/2018,Givosiran
Mid-2018;,Phase 3,ALXN,108.60,07/31/2018,Eculizumab
Mid-2018;,Phase 3,ATNX,14.12,07/31/2018,Oraxol
Mid-2018;,Phase 2,BLRX,0.97,07/31/2018,BL-8040
Mid-2018;,Phase 2,CMTX,10.00,07/31/2018,CX-072
Mid-2018;,Phase 1/2,CTMX,27.00,07/31/2018,CX 072
Mid-2018;,Phase 3,EBIO,0.81,07/31/2018,Vicinium
Mid-2018;,Phase 3,FOMX,6.20,07/31/2018,FMX103
Mid-2018;,Phase 3,FOMX,6.20,07/31/2018,FMX101 - FX2017-22
Mid-2018;,Phase 2,GNMX,2.27,07/31/2018,AEVI-001 (NFC-1)
Mid-2018;,Phase 1/2,GNMX,2.27,07/31/2018,AEVI-002 (Anti-LIGHT mAb)
Mid-2018;,Phase 2b,GSK,36.49,07/31/2018,Dezamizumab
Mid-2018;,Phase 3,GSK,36.49,07/31/2018,Dolutegravir + lamivudine (GEMINI 2)
Mid-2018;,Phase 3,GSK,36.49,07/31/2018,Dolutegravir + lamivudine (GEMINI 1)
2018;,Phase 1/2,JUNO,85.69,07/31/2018,Lico-cel (CD-19 JCAR017) - TRANSCEND
Mid-2018;,Phase 2,MRTX,27.10,07/31/2018,Sitravatinib plus nivolumab
Mid-2018;,Phase 2b,OBSV,12.19,07/31/2018,OBE2109 - EDELWEISS
Mid-2018;,Phase 1,PULM,1.51,07/31/2018,Pulmazole (PUR1900)
Mid-2018;,Phase 3,RDHL,5.70,07/31/2018,RHB-104 MAP US
Mid-2018;,Phase 2b,SCYX,1.69,07/31/2018,SCY-078 - oral
Mid-2018;,Phase 1/2,SNSS,5.55,07/31/2018,SNS-062
Mid-2018;,Phase 1,SPRO,11.88,07/31/2018,SPR994
Mid-2018;,Phase 1/2,SRPT,55.14,07/31/2018,SRP-5051
Mid-2018;,Phase 2b,VRNA,11.85,07/31/2018,RPL554
Mid-2018;,Phase 3,XLRN,39.23,07/31/2018,Luspatercept - BELIEVE
Mid-2018;,Phase 3,XLRN,39.23,07/31/2018,Luspatercept - MEDALIST
Mid-2018;,Phase 2,ZFGN,7.92,07/31/2018,ZGN-1061
,PDUFA priority review,SIGA,5.20,08/08/2018,TPOXX
,PDUFA priority review,ALNY,115.92,08/11/2018,Patisiran APOLLO
,PDUFA,REGN,336.38,08/11/2018,EYLEA
,PDUFA,KALA,12.47,08/24/2018,INVELTYS
,PDUFA,VRX,17.79,08/26/2018,IDP-121
,PDUFA,AKCA,21.49,08/30/2018,Volanesorsen - APPROACH
3Q 2018;,Phase 1/2,AGLE,5.45,09/30/2018,AEB1102
Late-3Q/Early-4Q est;,Phase 1/2,AGTC,3.95,09/30/2018,rAAV-hRS1
3Q 2018;,Phase 3,AMRN,3.48,09/30/2018,Vascepa REDUCE-IT outcomes trial
3Q 2018;,Phase 3,AQXP,15.31,09/30/2018,AQX-1125 LEADERSHIP
3Q 2018;,Phase 2,AXON,1.91,09/30/2018,Nelotanserin
3Q 2018;,Phase 3,CNCE,20.09,09/30/2018,AVP-786
3Q 2018;,Phase 2,EIGR,8.15,09/30/2018,Exendin 9-39
3Q 2018;,Phase 2,FLKS,4.17,09/30/2018,FLX-787 - COMMEND US trial
3Q 2018;,Phase 2,GILD,79.32,09/30/2018,GS-5734
3Q 2018;,Phase 3,HSGX,2.60,09/30/2018,NeoCart
3Q 2018;,Phase 2,NVO,50.07,09/30/2018,Concizumab - explorer
3Q 2018;,Phase 3,NVO,50.07,09/30/2018,Somapacitan (NN8640) - REAL 3
3Q 2018;,Phase 2,NVS,83.25,09/30/2018,INC280
3Q 2018;,Phase 3,PGNX,5.42,09/30/2018,1404
3Q 2018;,Phase 2,RGLS,1.11,09/30/2018,RG-012 - HERA
3Q 2018;,Phase 2,SMMT,10.60,09/30/2018,Ezutromid
3Q 2018;,Phase 3,TNXP,3.36,09/30/2018,TNX-102 SL
3Q 2018;,Phase 3,URGN,47.60,09/30/2018,MitoGel - OLYMPUS
3Q 2018;,Phase 3,VTL,5.10,09/30/2018,VTI-308
,PDUFA,LLY,76.23,10/10/2018,"Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN"
4Q 2018;,PDUFA,PRTK,12.65,10/19/2018,Sarecycline
,PDUFA,MRK,54.87,10/23/2018,Doravirine (MK-1439)
,PDUFA,TRVN,1.63,11/02/2018,Oliceridine (TRV130)
"Nov 16, 2018 est only;",PDUFA,NVS,83.25,11/16/2018,Adalimumab
,PDUFA,TBPH,27.95,11/30/2018,Revefenacin
2018;,Phase 3,ABBV,111.30,12/31/2018,ABT-494 - SELECT-COMPARE
2018;,Phase 3,ABBV,111.30,12/31/2018,Imbruvica - PHOENIX
2H 2018;,Phase 2b,ABLX,53.18,12/31/2018,ALX-0171
2H 2018;,Phase 2,ABUS,5.30,12/31/2018,"ARB-1467, tenofovir, and pegylated interferon"
2018;,Phase 1/2,ACIU,11.68,12/31/2018,ACI-24 (anti-Abeta vaccine)
YE 2018;,Phase 2,ACRS,19.01,12/31/2018,ATI-50002 - dose ranging
2H 2018;,Phase 1/2,ADVM,7.05,12/31/2018,ADVM-043
2H 2018;,Phase 3,AGN,162.77,12/31/2018,ABICIPAR
2H 2018;,Phase 3,AIMT,38.68,12/31/2018,AR101 RAMSES
YE 2018;,Phase 3,AKBA,14.11,12/31/2018,Vadadustat - TRILO2GY
YE 2018;,Phase 2,AKBA,14.11,12/31/2018,Vadadustat - FO2RWARD
2018;,Phase 2,AKCA,21.49,12/31/2018,AKCEA-ANGPTL3-LRx
2H 2018;,Phase 2b,AKCA,21.49,12/31/2018,AKCEA-APO(a)-LRx
2H 2018;,Phase 2b,ALDX,6.80,12/31/2018,ADX-102
2H 2018;,Phase 2b,ALDX,6.80,12/31/2018,ADX-102
2H 2018;,Phase 3,ALDX,6.80,12/31/2018,ADX-102
2H 2018;,Phase 2,ALDX,6.80,12/31/2018,ADX-102
2H 2018;,Phase 2,ALNA,6.91,12/31/2018,ALLN-177
2018;,Phase 1/2,ALNY,115.92,12/31/2018,ALN-CC5 (cemdisiran)
4Q 2018;,Phase 3,ALXN,108.60,12/31/2018,ALXN1210
2Q 2018;,Phase 3,ALXN,108.60,12/31/2018,ALXN1210
2H 2018;,Phase 3,AMGN,173.46,12/31/2018,ABP 710
2H 2018;,Phase 2,APLS,14.01,12/31/2018,APL-2 subcutaneous
2H 2018;,Phase 2,ARGX,75.10,12/31/2018,ARGX-113
2H 2018;,Phase 2,ARGX,75.10,12/31/2018,ARGX-113
YE 2018;,Phase 2b,ARMO,38.30,12/31/2018,AM0010 (PEG-IL-10) and Pembrolizumab - Cypress 1
YE 2018;,Phase 2b,ARMO,38.30,12/31/2018,AM0010 (PEG-IL-10) and Nivolumab - Cypress 2
2H 2018;,Phase 1/2,AST,1.95,12/31/2018,AST-VAC2
2H 2018;,Phase 1,ATNM,0.54,12/31/2018,Actimab-M
2H 2018;,Phase 2,ATNM,0.54,12/31/2018,Actimab-A
2018;,Phase 2,ATOS,0.59,12/31/2018,Endoxifen
2018;,Phase 2,ATOS,0.59,12/31/2018,Endoxifen
2H 2018;,Phase 2,AUPH,5.10,12/31/2018,Voclosporin
2H 2018;,Phase 2,AUPH,5.10,12/31/2018,Voclosporin
2H 2018;,Phase 3,AZN,33.61,12/31/2018,Lynparza
2H 2018;,Phase 3,AZN,33.61,12/31/2018,Farxiga - DECLARE
2H 2018;,Phase 3,AZN,33.61,12/31/2018,FASENRA (benralizumab) - TERRANOVA
2H 2018;,Phase 3,AZN,33.61,12/31/2018,Durvalumab +/- tremelimumab (NEPTUNE)
2H 2018;,Phase 3,AZN,33.61,12/31/2018,Anifrolumab
2018;,Phase 2,BIIB,316.78,12/31/2018,Raxatrigine - BIIB074 (Nav1.7 inhibitor)
2H 2018;,Phase 2,BIIB,316.78,12/31/2018,BAN2401 (Aβ mAb)
2018;,Phase 1/2,BIVV,103.05,12/31/2018,BIVV001 (EXTEN-A)
YE 2018;,Phase 2b,BLPH,2.03,12/31/2018,INOpulse delivery device
YE 2018;,Phase 2,BLPH,2.03,12/31/2018,INOpulse delivery device
2018;,Phase 3,BLPH,2.03,12/31/2018,INOpulse delivery device
,Phase 2,BLRX,0.97,12/31/2018,BL-8040 in combination with KEYTRUDA - COMBAT trial
2018;,Phase 2b,BLRX,0.97,12/31/2018,BL-8040
2H 2018;,Phase 3,BMY,62.70,12/31/2018,CM-602 – Opdivo + Elo + SOC
2H 2018;,Phase 3,BMY,62.70,12/31/2018,CM-459 – Opdivo
2H 2018;,Phase 3,BMY,62.70,12/31/2018,CM-451 – Opdivo + Yervoy
2018;,Phase 3,BYSI,27.00,12/31/2018,Plinabulin
2H 2018;,Phase 2,CANF,2.02,12/31/2018,Namodenoson (CF102)
2018;,Phase 2,CASC,9.99,12/31/2018,Tucatinib - MOUNTAINEER
2018;,Phase 3,CELG,92.51,12/31/2018,OTEZLA - SPSO-001
2018;,Phase 3,CELG,92.51,12/31/2018,REVLIMID - ROBUST
2H 2018;,Phase 3,CELG,92.51,12/31/2018,Oral Azacitidine - CC-486-AML-001
2018;,Phase 3,CELG,92.51,12/31/2018,ABRAXANE - PANC-003 apact
2018;,Phase 3,CELG,92.51,12/31/2018,ABRAXANE - IMpower 130 ( I/O Combo)
2018;,Phase 3,CELG,92.51,12/31/2018,ABRAXANE - IMpower 131 ( I/O Combo)
2018;,Phase 3,CELG,92.51,12/31/2018,ABRAXANE - IMPassion ( I/O Combo)
4Q 2018;,Phase 2,CFRX,1.46,12/31/2018,CF-301
2H 2018;,Phase 2,CMRX,4.90,12/31/2018,IV Brincidofovir
2H 2018;,Phase 2,CMTX,10.00,12/31/2018,CX-2009 - PROCLAIM
2H 2018;,Phase 2,CNAT,5.06,12/31/2018,Emricasan
2H 2018;,Phase 2a,CNCE,20.09,12/31/2018,CTP-543
2H 2018;,Phase 1/2,CTMX,27.00,12/31/2018,CX 2009
2H 2018;,Phase 1,DCPH,26.07,12/31/2018,DCC-3014
4Q 2018;,Phase 3,EGRX,56.81,12/31/2018,Fulvestrant
2H 2018;,Phase 2,EIGR,8.15,12/31/2018,Ubenimex - ULTRA
2018;,Phase 2,EPZM,16.00,12/31/2018,Tazemetostat
4Q 2018;,Phase 3,ESPR,69.46,12/31/2018,Bempedoic Acid/ Ezetimibe (1002FDC-053)
2H 2018;,Phase 3,FGEN,50.70,12/31/2018,Roxadustat - ANDES
2018;,Phase 2,FLKS,4.17,12/31/2018,FLX-787
2H 2018;,Phase 2,FLXN,21.92,12/31/2018,Zilretta - SHIP
2H 2018;,Phase 2,GEMP,6.38,12/31/2018,Gemcabene - AZURE-1
4Q 2018;,Phase 2,GILD,79.32,12/31/2018,Tirabrutinib (GS-4059)
2H 2018;,Phase 2,GILD,79.32,12/31/2018,Axicabtagene ciloleucel - KTE-C19 (ZUMA-2)
2018;,Phase 3,GLYC,22.32,12/31/2018,GMI-1070 (rivipansel)
2H 2018;,Phase 3,GSK,36.49,12/31/2018,Dolutegravir + rilpivirine
4Q 2018;,Phase 2,GTHX,19.38,12/31/2018,Trilaciclib
YE 2018;,Phase 2,GTXI,14.51,12/31/2018,Enobosarm
2H 2018;,Phase 3,GWPH,126.06,12/31/2018,Epidiolex
2H 2018;,Phase 3,GWPH,126.06,12/31/2018,Epidiolex
Late 4Q 2018;,Phase 3,HALO,17.17,12/31/2018,PEGPH20 - HALO-301
2018;,Phase 1b,HALO,17.17,12/31/2018,PEGPH20 in combination with KEYTRUDA
2018;,Phase 3,IMGN,8.91,12/31/2018,Kadcyla (KATHERINE).
4Q 2018;,Phase 2,IMRN,7.54,12/31/2018,IMM-124E
4Q 2018;,Phase 1/2,IMRN,7.54,12/31/2018,IMM-529
YE 2018;,Phase 2,INSY,7.65,12/31/2018,Cannabidiol
2018;,Phase 3,JNJ,129.53,12/31/2018,STELARA (USTEKINUMAB)
2018;,Phase 1,JUNO,85.69,12/31/2018,JCARH125
2H 2018;,Phase 2b,KPTI,13.06,12/31/2018,Selinexor - SADAL
2018;,Phase 3,LLY,76.23,12/31/2018,Ramucirumab
2018;,Phase 3,LLY,76.23,12/31/2018,Ramucirumab
2018;,Phase 3,LLY,76.23,12/31/2018,Empagliflozin
2018;,Phase 3,LLY,76.23,12/31/2018,Ixekizumab
2018;,–,LLY,76.23,12/31/2018,Tradjenta (linagliptin) - CARMELINA CV outcomes
2018;,Phase 3,LLY,76.23,12/31/2018,Ultra rapid insulin
2018;,Phase 3,LLY,76.23,12/31/2018,Tanezumab
2018;,Phase 3,LLY,76.23,12/31/2018,Ramucirumab
2018;,Phase 3,LLY,76.23,12/31/2018,Flortaucipir F 18 (Tau imaging agent)
2H 2018;,Phase 2,MACK,10.00,12/31/2018,MM-121 (SHERBOC)
2H 2018;,Phase 2,MACK,10.00,12/31/2018,MM-121
2018;,Phase 1/2,MBRX,1.68,12/31/2018,Annamycin
Late 2018 or early 2019;,Phase 2,MNLO,35.65,12/31/2018,Serlopitant
Late 2018 or early 2019;,Phase 2,MNLO,35.65,12/31/2018,Serlopitant
2018;,Phase 2,MRNS,6.01,12/31/2018,Ganaxolone
Late-2018;,Phase 2b,NBIX,79.28,12/31/2018,INGREZZA - T-Force GOLD
2018;,Phase 1,NCNA,20.56,12/31/2018,NUC-3373
2018;,Phase 2,NCNA,20.56,12/31/2018,NUC-1031 (Acelarin)
2018;,Phase 1/2,NITE,12.44,12/31/2018,NSR-RPGR
4Q 2018 or 1Q 2019;,Phase 3,NVAX,1.98,12/31/2018,RSV vaccine - prepare trial
2018;,Phase 2,NVCR,20.95,12/31/2018,Tumor Treating Fields (TTFields) STELLAR
2H 2018;,Phase 3,NVS,83.25,12/31/2018,BYL719
2H 2018;,Phase 2,NVS,83.25,12/31/2018,LIK066
2H 2018;,Phase 3,NVS,83.25,12/31/2018,Entresto - PARAGON
YE 2018;,Phase 2a,OBSV,12.19,12/31/2018,OBE022 - PROLONG
2H 2018;,Phase 3,OCUL,5.03,12/31/2018,OTX-TP
2018;,Phase 2b,ONCS,1.64,12/31/2018,ImmunoPulse IL-12 - PISCES
2H 2018;,Phase 2,OVID,6.80,12/31/2018,OV101 (STARS)
2H 2018;,Phase 2a,PIRS,8.59,12/31/2018,PRS-080
2018;,Phase 1/2,PRQR,2.90,12/31/2018,QR-010
4Q 2018;,Phase 2a,PULM,1.51,12/31/2018,PUR1800
YE 2018;,Phase 3,QURE,19.17,12/31/2018,AMT-061
2H 2018;,Phase 1/2,RARE,44.47,12/31/2018,DTX301
2H 2018;,Phase 3,RDHL,5.70,12/31/2018,RHB-105 - ERADICATE Hp 2
2H 2018;,Phase 2,REGN,336.38,12/31/2018,Cemiplimab
4Q 2018;,Phase 3,REGN,336.38,12/31/2018,Dupixent (dupilumab)
2H 2018;,Phase 3,RETA,26.22,12/31/2018,Bardoxolone methyl - CATALYST
Late 2018;,Phase 1/2,RGNX,25.70,12/31/2018,RGX-501
2018;,Phase 2,RIGL,3.79,12/31/2018,Fostamatinib
2H 2018;,Phase 3,RVNC,29.70,12/31/2018,"RT002 - SAKURA 1, 2 and 3"
4Q 2018;,Phase 2,SAGE,152.15,12/31/2018,SAGE-217
4Q 2018;,Phase 3,SBBP,6.60,12/31/2018,COR-003 (levoketoconazole) - LOGICS
4Q 2018;,Phase 3,SCYX,1.69,12/31/2018,SCY-078 - oral - CARES
4Q 2018;,Phase 3,SCYX,1.69,12/31/2018,SCY-078 - oral (FURI)
2018;,Phase 3,SGEN,50.14,12/31/2018,ADCETRIS in combination with chemotherapy - ECHELON-2
2018;,Phase 1/2,SGMO,19.60,12/31/2018,SB-FIX
2H 2018;,Phase 3,SNGX,1.97,12/31/2018,SGX301 (synthetic hypericin)
2H 2018;,Phase 3,SNNA,14.40,12/31/2018,SNA-001
2H 2018;,Phase 3,SNNA,14.40,12/31/2018,SNA-001
4Q 2018;,Phase 3,SNY,38.98,12/31/2018,Isatuximab
2H 2018;,Phase 3,SPPI,20.17,12/31/2018,SPI-2012 (ROLONTIS)
2H 2018;,Phase 1/2,SRPT,55.14,12/31/2018,Microdystrophin gene therapy rAAVrh74.MCK.GALGT2
2H 2018;,Phase 1/2,SRPT,55.14,12/31/2018,GALGT2 gene therapy
YE 2018;,Phase 3,SVRA,11.70,12/31/2018,Molgradex - IMPALA
2H 2018;,Phase 1,SYBX,9.54,12/31/2018,SYNB1618
YE 2018;,Phase 1/2,SYBX,9.54,12/31/2018,SYNB1020
2018;,Phase 2,TCON,2.90,12/31/2018,TRC105
2018;,Phase 2,TCON,2.90,12/31/2018,TRC102
2H 2018;,Phase 3,TCON,2.90,12/31/2018,TRC105 (TAPPAS)
2H 2018;,Phase 2b,TORC,17.00,12/31/2018,RTB101 and Everolimus
2H 2018;,Phase 1/2,TSRO,58.89,12/31/2018,Niraparib - AVANOVA
2H 2018;,Phase 2,TYME,3.99,12/31/2018,SM-88
2018;,Phase 3,UTHR,128.71,12/31/2018,Esuberaprost - BEAT
2H 2018;,Phase 3,UTHR,128.71,12/31/2018,Orenitram
YE 2018;,Phase 2,VNDA,15.63,12/31/2018,Tradipitant
2018;,Phase 3,VNDA,15.63,12/31/2018,HETLIOZ (tasimelteon)
2H 2018;,Phase 2,VTGN,1.16,12/31/2018,AV-101
YE 2018;,Phase 2,XBIT,4.17,12/31/2018,XBIO-101
4Q 2018;,Phase 2,XNCR,21.70,12/31/2018,XmAb5871
2H 2018;,Phase 3,ZEAL,15.28,12/31/2018,Dasiglucagon
,Phase 2a,ANAB,104.33,02/17/2019,ANB020
Early 2019;,Phase 3,AIMT,38.68,03/31/2019,AR101 ARTEMIS
1Q 2019;,Phase 3,ASND,50.10,03/31/2019,TransCon
Early 2019;,Phase 2,CLBS,3.85,03/31/2019,CLBS03
1Q 2019;,Phase 3,CLSD,5.77,03/31/2019,Suprachoroidal CLS-TA - SAPPHIRE
1Q 2019;,Phase 3,CLSN,2.12,03/31/2019,ThermoDox - OPTIMA
Early 2019;,Phase 3,CTXR,3.34,03/31/2019,Mino-Lok
1Q 2019;,Phase 3,EVFM,7.20,03/31/2019,Amphora - AMPOWER
1Q 2019;,Phase 2b,GSK,36.49,03/31/2019,Danirixin
1Q 2019;,Phase 1/2,IMRN,7.54,03/31/2019,IMM-529
Early 2019;,Phase 2b,ORMP,7.72,03/31/2019,ORMD-0801
1Q 2019;,Phase 3,PRTO,2.25,03/31/2019,Vonapanitase (PRT-201) PATENCY-2
1Q 2019;,Phase 2a,RNN,1.90,03/31/2019,RX-3117 in combination with Abraxane
1H 2019;,Phase 1,ATRA,41.70,06/30/2019,ATA188
1H 2019;,Phase 3,ATRA,41.70,06/30/2019,ATA 129 - ALLELE
1H 2019;,Phase 3,BMY,62.70,06/30/2019,CM-714 Opdivo + Yervoy
2H 2018 – 1H 2019;,Phase 2,BMY,62.70,06/30/2019,CM-568 - Opdivo + Yervoy
1H 2019;,–,CMRX,4.90,06/30/2019,Oral Brincidofovir
1H 2019;,Phase 2,CNAT,5.06,06/30/2019,Emricasan
1H 2019;,Phase 2b,DERM,26.79,06/30/2019,Lebrikizumab
1H 2019;,Phase 2,FBIO,3.63,06/30/2019,CEVA101
1H 2019;,Phase 3,GBT,57.15,06/30/2019,GBT440 - HOPE
1H 2019;,Phase 2,GILD,79.32,06/30/2019,GS-9877
2Q 2019;,Phase 3,GILD,79.32,06/30/2019,F/TAF (Descovy)
1H 2019;,Phase 3,GSK,36.49,06/30/2019,Tapinarof (GSK2894512)
1H 2019;,Phase 2b,GSK,36.49,06/30/2019,Inhaled PI3Kδ inhibitor (Nemiralisib)
1H 2019;,Phase 3,ICPT,54.21,06/30/2019,Ocaliva (Obeticholic acid (OCA)) - REGENERATE
1H 2019;,Phase 3,NERV,5.55,06/30/2019,MIN-101
1H 2019;,Phase 2,RARX,6.30,06/30/2019,RA101495
1H 2019;,Phase 3,RYTM,25.76,06/30/2019,Setmelanotide
1H 2019;,Phase 1/2,SLDB,25.66,06/30/2019,SGT-001
1H 2019;,Phase 1/2,SNDX,8.98,06/30/2019,Entinostat plus Tecentriq - ENCORE 603
1H 2019;,Phase 3,SNGX,1.97,06/30/2019,SGX942 (dusquetide)
1H 2019;,Phase 2b,SNNA,14.40,06/30/2019,SNA-120
2018/19;,Phase 3,TBPH,27.95,06/30/2019,Telavancin
1H 2019;,Phase 2/3,TGTX,11.75,06/30/2019,TG-1101 and TGR-1202 - UNITY-NHL study
1H 2019;,Phase 2,VTGN,1.16,06/30/2019,AV-101
Mid-2019;,Phase 3,TBPH,27.95,07/31/2019,Closed Triple - CAPTAIN
2019;,Phase 3,ABBV,111.30,12/31/2019,Venetoclax
2019;,Phase 1/2,ADXS,2.63,12/31/2019,Axalimogene filolisbac + durvalumab
2019;,Phase 2,AFMD,2.40,12/31/2019,AFM13
2019;,Phase 3,AGN,162.77,12/31/2019,RAPASTINEL
2019;,Phase 3,AKBA,14.11,12/31/2019,Vadadustat - INNO2VATE
2019;,Phase 3,AKBA,14.11,12/31/2019,Vadadustat - PRO2TECT
2019;,Phase 2,AKCA,21.49,12/31/2019,AKCEA-ANGPTL3-LRx
2019;,Phase 2b,AKCA,21.49,12/31/2019,AKCEA-APOCIII-LRx
2H 2019;,Phase 3,ALNA,6.91,12/31/2019,ALLN-177
2019;,Phase 3,AMGN,173.46,12/31/2019,KYPROLIS (ARROW)
2H 2019;,Phase 3,ATNM,0.54,12/31/2019,Iomab-B
2019;,Phase 3,AZN,33.61,12/31/2019,Imfinzi + tremelimumab  (POSEIDON)
2019;,Phase 3,AZN,33.61,12/31/2019,Imfinzi + tremelimumab (CASPIAN)
2019;,Phase 3,AZN,33.61,12/31/2019,Imfinzi + tremelimumab  (DANUBE)
2019;,Phase 3,AZN,33.61,12/31/2019,Lynparza - SOLO 3
2019;,Phase 3,AZN,33.61,12/31/2019,Farxiga (Dapa-HF)
2019;,Phase 3,AZN,33.61,12/31/2019,Lanabecestat (AZD3293) - AMARANTH
2019;,Phase 3,AZN,33.61,12/31/2019,Durvalumab +/- tremelimumab (DANUBE)
2019;,Phase 3,AZN,33.61,12/31/2019,Brilinta (THEMIS)
Late 2019;,Phase 3,BCLI,3.12,12/31/2019,NurOwn
2H 2019;,Phase 3,BMRN,80.33,12/31/2019,Vosoritide
2019;,Phase 3,BMY,62.70,12/31/2019,CM-649 – Opdivo+ Yervoy or Chemo
2H 2019;,Phase 3,BMY,62.70,12/31/2019,CM-9LA Opdivo + Yervoy + Chemo
2019;,Phase 3,BMY,62.70,12/31/2019,CM-651 – Opdivo + Yervoy
2019;,Phase 3,CELG,92.51,12/31/2019,REVLIMID - MAGNIFY NHL-010
2019;,Phase 3,CHMA,1.50,12/31/2019,Mycapssa - OPTIMAL
2019;,Phase 2b,CNAT,5.06,12/31/2019,Emricasan
2019;,Phase 3,DCPH,26.07,12/31/2019,DCC-2618 - INVICTUS
2H 2019;,Phase 2,GILD,79.32,12/31/2019,GS-9876
2019;,Phase 3,GSK,36.49,12/31/2019,Mepolizumab - SYNAPSE
2019;,Phase 3,IMGN,8.91,12/31/2019,Kadcyla (KAITLIN)
2019;,Phase 2b,IMMP,1.74,12/31/2019,Eftilagimod Alpha  - Active Immunotherapy PAClitaxel (AIPAC)
2019;,Phase 2,IMRN,7.54,12/31/2019,IMM-124E
2019;,Phase 3,INCY,84.50,12/31/2019,Ruxolitinib - REACH 3
2019;,Phase 3,INCY,84.50,12/31/2019,Ruxolitinib - REACH 2
2019;,Phase 3,JNJ,129.53,12/31/2019,INVOKANA - CREDENCE
2019;,Phase 3,JNJ,129.53,12/31/2019,DARZALEX (Daratumumab)
2H 2019;,Phase 2,KALV,10.61,12/31/2019,KVD001
2H 2019;,Phase 1/2,KMDA,5.00,12/31/2019,Alpha-1 antitrypsin (AAT)
2H 2019;,Phase 2,KMDA,5.00,12/31/2019,Alpha-1 antitrypsin (AAT)
2019;,Phase 2/3,KPTI,13.06,12/31/2019,Selinexor - SEAL
2019;,Phase 3,KPTI,13.06,12/31/2019,Selinexor - BOSTON
2019;,Phase 3,LXRX,9.29,12/31/2019,Sotagliflozin
2H 2019;,–,MDCO,30.84,12/31/2019,Inclisiran - ORION 11
2019;,Phase 3,MRK,54.87,12/31/2019,MK-8931 (019) - Verubecestat
2019;,Phase 3,NVS,83.25,12/31/2019,QVM149
2019;,Phase 3,NVS,83.25,12/31/2019,QAW039 (fevipiprant)
2019;,Phase 3,NVS,83.25,12/31/2019,OMB157 (ofatumumab)
2019;,Phase 3,NVS,83.25,12/31/2019,Entresto - PARADISE
2H 2019;,Phase 3,OBSV,12.19,12/31/2019,OBE2109 - PRIMROSE 2
2H 2019;,Phase 3,OBSV,12.19,12/31/2019,OBE2109 - PRIMROSE
2019;,Phase 3,ONTX,1.02,12/31/2019,IV Rigosertib - INSPIRE
2H 2019;,Phase 2a,OPHT,2.79,12/31/2019,Zimura
2019;,Phase 1/2,OVAS,0.97,12/31/2019,OvaPrime
2019;,Phase 2,REGN,336.38,12/31/2019,Cemiplimab
2H 2019;,Phase 3,RETA,26.22,12/31/2019,Bardoxolone methyl - CARDINAL
2H 2019;,Phase 2,RETA,26.22,12/31/2019,Omaveloxolone - MOXIe
2019;,Phase 2,SLGL,10.60,12/31/2019,TWIN
2019;,Phase 2,SLGL,10.60,12/31/2019,VERED
4Q 2019;,Phase 2,SLS,5.26,12/31/2019,NeuVax in combination with Herceptin
2019;,Phase 3,SNY,38.98,12/31/2019,NeoGAA - COMET
2019;,Phase 2/3,SNY,38.98,12/31/2019,Olipudase alfa
2H 2019;,Phase 3,VBIV,3.85,12/31/2019,Sci-B-Vac - PROTECT
2019;,Phase 2/3,ZYNE,11.33,12/31/2019,ZYN002
2020/21;,Phase 3,ADXS,2.63,06/30/2020,Axalimogene filolisbac - AIM2CERV Trial
1H 2020;,Phase 2b,GSK,36.49,06/30/2020,GSK 165
1H 2020;,Phase 3,MNK,16.02,06/30/2020,Terlipressin
1H 2020;,Phase 2,MNK,16.02,06/30/2020,H.P. Acthar Gel
1H 2020;,Phase 3,MNK,16.02,06/30/2020,UVADEX (methoxsalen) and Therakos
1H 2020;,Phase 3,MNLO,35.65,06/30/2020,Serlopitant
2020;,Phase 3,AGN,162.77,12/31/2020,RELAMORELIN
2020;,Phase 3,AZN,33.61,12/31/2020,Farxiga (Dapa-CKD)
2020;,Phase 3,AZN,33.61,12/31/2020,Durvalumab (ADJUVANT)
2020;,Phase 3,BLRX,0.97,12/31/2020,BL-8040 GENESIS
2020;,Phase 3,CATB,1.23,12/31/2020,Edasalonexent (CAT-1004)
2020;,Phase 3,CELG,92.51,12/31/2020,REVLIMID - MAGNIFY NHL-008
2020;,Phase 3,CHMA,1.50,12/31/2020,Mycapssa - MPOWERED
2020;,Phase 3,CRBP,7.05,12/31/2020,Anabasum (Resunab)
2H 2020;,Phase 3,GSK,36.49,12/31/2020,Daprodustat - ASCEND-D
2020;,Phase 2,KZIA,4.25,12/31/2020,GDC-0084
2020;,Phase 3,NVCR,20.95,12/31/2020,Tumor Treating Fields (TTFields) METIS
2020;,Phase 3,ODT,15.44,12/31/2020,Tesetaxel - CONTESSA
2020;,Phase 2b,OPHT,2.79,12/31/2020,Zimura
2020;,Phase 3,PRTA,28.19,12/31/2020,NEOD001 VITAL
2020;,Phase 3,SNY,38.98,12/31/2020,Efpeglenatide
2021;,Phase 3,NVCR,20.95,12/31/2021,Tumor Treating Fields (TTFields) LUNAR
2021;,Phase 3,REGN,336.38,12/31/2021,Cemiplimab
2021;,Phase 3,REGN,336.38,12/31/2021,Dupixent (dupilumab)
2021;,Phase 2,SLGL,10.60,12/31/2021,SIRS-T
2022;,Phase 3,NVS,83.25,12/31/2022,Cosentyx (secukinumab) - SURPASS
2024;,Phase 2/3,NVS,83.25,12/31/2024,CNP 520
